{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Willmann JK"],"funding":["NCI NIH HHS"],"pagination":["2133-2140"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5493049"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["35(19)"],"pubmed_abstract":["Purpose We performed a first-in-human clinical trial on ultrasound molecular imaging (USMI) in patients with breast and ovarian lesions using a clinical-grade contrast agent (kinase insert domain receptor [KDR] -targeted contrast microbubble [MB<sub>KDR</sub>]) that is targeted at the KDR, one of the key regulators of neoangiogenesis in cancer. The aim of this study was to assess whether USMI using MB<sub>KDR</sub> is safe and allows assessment of KDR expression using immunohistochemistry (IHC) as the gold standard. Methods Twenty-four women (age 48 to 79 years) with focal ovarian lesions and 21 women (age 34 to 66 years) with focal breast lesions were injected intravenously with MB<sub>KDR</sub> (0.03 to 0.08 mL/kg of body weight), and USMI of the lesions was performed starting 5 minutes "],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results."],"pmcid":["PMC5493049"],"funding_grant_id":["R01 CA155289","U54 CA151459","U54 CA119367","U54 CA199075"],"pubmed_authors":["Martini M","Valluru KS","Lutz AM","Testa AC","Willmann JK","Bonomo L","Rindi G","Rinaldi P","Gambhir SS","Petrone G"],"additional_accession":[]},"is_claimable":false,"name":"Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results.","description":"Purpose We performed a first-in-human clinical trial on ultrasound molecular imaging (USMI) in patients with breast and ovarian lesions using a clinical-grade contrast agent (kinase insert domain receptor [KDR] -targeted contrast microbubble [MB<sub>KDR</sub>]) that is targeted at the KDR, one of the key regulators of neoangiogenesis in cancer. The aim of this study was to assess whether USMI using MB<sub>KDR</sub> is safe and allows assessment of KDR expression using immunohistochemistry (IHC) as the gold standard. Methods Twenty-four women (age 48 to 79 years) with focal ovarian lesions and 21 women (age 34 to 66 years) with focal breast lesions were injected intravenously with MB<sub>KDR</sub> (0.03 to 0.08 mL/kg of body weight), and USMI of the lesions was performed starting 5 minutes ","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Jul","modification":"2025-04-04T09:53:54.672Z","creation":"2019-03-26T23:02:43Z"},"accession":"S-EPMC5493049","cross_references":{"pubmed":["28291391"],"doi":["10.1200/JCO.2016.70.8594","10.1200/jco.2016.70.8594"]}}